New price targets for Genmab and Zealand Pharma, Ascendis UK approval, and cannabis in new form

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week, Genmab and Zealand Pharma received new price targets, Ascendis Pharma got approval in the U.K. for YORVIPATH/TransCon, the cannabis healthcare company CS Medica announced a partnership with a distributor for Germany and the Gulf, and Expres2ion got MSEK 22.5 in dividend payments strengthening their cash position. The best stock of the week rose 88%.

9 of the 21 Danish companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is now the best-performing Danish healthcare stock year-to-date with a 126% return and cannabis company DanCann Pharma was the best Nordic healthcare investment last week.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.



Acarix AB’s Annual Report 2023 (Link)

Ascendis Pharma

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 (Link)

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism (Link)


No news the past week


No news the past week

CS Medica

CS MEDICA A/S: CEO, Lone Henriksen, buys shares in the Company (Link)

CS MEDICA Advances Global Reach with 180˚ Drug Store Alliance, Powered by Pull Market Strategy (Link)


No news the past week

Evaxion Biotech

No news the past week


ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS (Link)


No news the past week


HSBC lowered their price target from DKK 3190 to 2970 and Goldman Sahcs lowered theirs from DKK 2284 to 2218.


No news the past week

Initiator Pharma

No news the past week

IO Biotech

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Link)

Pila Pharma

No news the past week


Notice of Saniona AB annual shareholders’ meeting (Link)

Scandion Oncology

No news the past week

SynAct Pharma

Bulletin from the extraordinary general meeting of SynAct Pharma AB (Link)


Resolutions from the Annual General Meeting of ViroGates A/S (Link)

Zealand Pharma

Nordea raised their price target from DKK 570 to 764.

Y-mAbs Therapeutics

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 (Link)


No news the past week



On average, the Danish biotech and healthcare stocks delivered a negative share price performance the past week of 1.0%. During the week, Ascendis Pharma got YORVIPATH/TransCon approved in the U.K. as well as orphan drug status, CS Medica announced a partnership with a distributor for Germany and the Gulf, Expres2ion to receive SEKKM 22.5 in dividend payments from 34% owned subsidiary AdaptVac ApS as a consequence of an EURM 10 milestone payment from Bavarian Nordic. Finally, new price targets were initiated. Small downgrades for Genmab and a big upgrade for Zealand Pharma.

Pila Pharma fell 19% dragging the index down. The company did not report any news, but should rather be seen as a drawback following last week’s increase of 50%. The best stocks year-to-date continue to be Gubra and Y-mAbs Therapeutics with 126-116% increases after the first 4 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 2.8%.

Overview of share price developments the past week, year-to-date, and last twelve months


The past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 1.7% to 60.41. The index was recovering from its all-time low in October of 57.12 but has since been on a downward trajectory towards the all-time low again. In the past 12 months, the index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

4487% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

DanCann Pharma A/S (87%) focuses on discovering, developing, producing and commercialising novel cannabinoid drugs in a wide range of disease areas. The company produces and distributes prescription and over-the-counter (OTC) medicines, mainly focused on pain patients with alternative needs and treatment of their disease, covered by the Danish pilot programme for medicinal cannabis. The stock rose without any company specific news.

Q Linea AB (60%) specializes in the research and development of instruments and consumables. The products are mainly used in the treatment of infectious diseases and blood poisoning and include diagnostic and analysis tools, as well as other related basic sample handling. The technology is based on the so-called ID and AST technology. The rise came following after they received US FDA 510(k) clearance for the ASTar® System.

Sedana Medical AB (44%) is a MedTech company. The company currently works with AnaConDa technology, which includes the transformation of liquid into gas. The technique is usually used for intensive care patients during anesthesia and differs from the traditional treatment previously given intravenously with drugs. The stock rose following their Q1 report (Link).

Sources: Refinitiv Eikon, Cision, Nordnet & company websites


Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.


Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email.